77
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Characteristics and Outcomes of Contacts of COVID-19 Patients Monitored Using an Automated Symptom Monitoring Tool — Maine, May–June 2020

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), is spread from person to person ( 1 – 3 ). Quarantine of exposed persons (contacts) for 14 days following their exposure reduces transmission ( 4 – 7 ). Contact tracing provides an opportunity to identify contacts, inform them of quarantine recommendations, and monitor their symptoms to promptly identify secondary COVID-19 cases ( 7 , 8 ). On March 12, 2020, Maine Center for Disease Control and Prevention (Maine CDC) identified the first case of COVID-19 in the state. Because of resource constraints, including staffing, Maine CDC could not consistently monitor contacts, and automated technological solutions for monitoring contacts were explored. On May 14, 2020, Maine CDC began enrolling contacts of patients with reported COVID-19 into Sara Alert (MITRE Corporation, 2020),* an automated, web-based, symptom monitoring tool. After initial communication with Maine CDC staff members, enrolled contacts automatically received daily symptom questionnaires via their choice of e-mailed weblink, text message, texted weblink, or telephone call until completion of their quarantine. Epidemiologic investigations were conducted for enrollees who reported symptoms or received a positive SARS-CoV-2 test result. During May 14–June 26, Maine CDC enrolled 1,622 contacts of 614 COVID-19 patients; 190 (11.7%) eventually developed COVID-19, highlighting the importance of identifying, quarantining, and monitoring contacts of COVID-19 patients to limit spread. In Maine, symptom monitoring was not feasible without the use of an automated symptom monitoring tool. Using a tool that permitted enrollees to specify a method of symptom monitoring was well received, because the majority of persons monitored (96.4%) agreed to report using this system. Public health investigators interviewed persons with COVID-19 upon report of the case to Maine CDC to collect information about their contacts, including date of last exposure. Contacts were defined as persons who were within 6 feet of an infectious person † for ≥15 minutes (≥30 minutes before May 29). Data were stored in the National Electronic Disease Surveillance Base System (NBS) § and sent to Maine CDC’s contact tracing team within 24 hours, along with contact data reported to Maine CDC by other jurisdictions and CDC’s Division of Global Migration and Quarantine. The contact tracing team telephoned contacts to provide quarantine recommendations, ¶ enroll them in Sara Alert, and instruct them to report symptoms daily via the Sara Alert questionnaire for the remainder of their quarantine. If contacts refused automated monitoring or could not be enrolled because of language barriers, they would be monitored using direct monitoring. Per the Council of State and Territorial Epidemiologists’ case definition,** monitored signs and symptoms included cough, difficulty breathing, fever, chills, shaking with chills (rigors), muscle pain, headache, sore throat, and new loss of taste or smell. The contact tracing team attempted to directly monitor contacts who refused or were unable to be enrolled. Maine CDC staff members conducted case investigations for all enrollees who sought SARS-CoV-2 molecular testing and had a positive result (confirmed cases) irrespective of symptoms and those who did not have molecular testing but reported symptoms (probable cases). Staff members attempted to call or text enrollees who did not respond to the questionnaire within 24 hours. Enrollees who did not report symptoms during their quarantine period were automatically released from quarantine by a Sara Alert–issued notice. Data for contacts enrolled during May 14–June 26, 2020, were extracted from Sara Alert. Enrollee demographic characteristics and Sara Alert program preferences, selected by enrollees at the time of enrollment, were analyzed, and the number of persons enrolled per household were calculated based on self-reported address. All persons enrolled in Sara Alert during the study period were matched to NBS records using date of birth and the first initial of their first and last names. NBS data were extracted on July 10 to allow contacts enrolled by June 26 to complete 14 days of quarantine. Data extracted from NBS included case status (confirmed or probable), hospitalization status, and outcome, including death. For most analyses, confirmed and probable cases were combined. SAS (version 9.3; SAS Institute) was used to conduct analyses. This activity was determined to meet the requirements of public health surveillance as defined in 45 CFR 46.102(l)(2). During May 14–June 26, 2020, Maine enrolled 1,622 contacts (enrollees) of 614 COVID-19 patients in Sara Alert. The average number of enrollees per index patient was 2.9 (range = 0–31). Among enrollees, median age was 29 years (range = 0–93 years); 766 (50.3%) were female (Table 1). Race data were available for 1,240 (76.4%) enrollees, 732 (59.0%) of whom identified as white and 486 (39.2%) as black/African American. Ethnicity data were available for 1,020 (62.9%) enrollees, 42 (4.1%) of whom identified as Hispanic/Latino. Primary language was documented for 1,230 (75.8%) enrollees; 985 (80.1%) primarily spoke English, 86 (7.0%) French, and 81 (6.6%) Somali. TABLE 1 Characteristics of contacts* of confirmed or probable COVID-19 † patients enrolled in an automated, web-based symptom monitoring tool (Sara Alert) — Maine, May 14–June 26, 2020 Characteristic No. (%) Total no. of persons enrolled 1,622 (100) Age at enrollment, yrs, median (range) 29 (0–93) Sex Female 766 (50.3) Male 757 (49.7) Not reported 99 (—) Race American Indian/Alaska Native 5 (0.4) Asian/Pacific Islander 17 (1.4) Black/African American 486 (39.2) White 732 (59.0) Not reported 382 (—) Ethnicity Hispanic or Latino 42 (4.1) Not Hispanic or Latino 978 (95.9) Not reported 602 (—) Primary language American Sign Language 6 (0.5) Arabic 8 (0.7) English 985 (80.1) French 86 (7.0) Kirundi 8 (0.7) Lingala 11 (0.9) Portuguese 10 (0.8) Somali 81 (6.6) Spanish 19 (1.5) Other 16 (1.4) Not reported 392 (—) County Androscoggin 421 (26.9) Aroostook 39 (2.5) Cumberland 713 (45.6) Franklin 12 (0.8) Hancock 2 (0.3) Kennebec 60 (3.8) Knox 1 (0.1) Lincoln 8 (0.5) Oxford 32 (2.1) Penobscot 17 (1.1) Sagadahoc 25 (1.6) Somerset 9 (0.6) Waldo 3 (0.2) Washington 14 (0.9) York 193 (12.4) Out of state 10 (0.6) Missing 59 (—) Abbreviation: COVID-19 = coronavirus disease 2019. * Defined as persons who were within 6 feet of an infectious person (symptomatic persons, 2 days before symptom onset to at least 10 days following symptom onset; asymptomatic persons, 2 days before collection of a specimen that resulted in a positive test to 10 days following specimen collection date) for ≥15 minutes (≥30 minutes before May 29). † Probable cases had either clinical criteria or epidemiologic evidence of exposure (contact with a person with a confirmed or probable COVID-19 case or contact with a person with clinically compatible illness or linkage to a person with confirmed COVID-19), or met vital records criteria (a death certificate listing COVID-19 or SARS-CoV-2 as a cause of death or a significant condition contributing to death with no confirmatory laboratory testing performed for COVID-19). Confirmed cases had confirmatory laboratory evidence of SARS-CoV-2 infection. COVID-19 signs and symptoms included cough, difficulty breathing, fever, chills, shaking with chills (rigors), muscle pain, headache, sore throat, and new loss of taste or smell. Overall, 475 (29.3%) of 1,622 enrollees were enrolled within 2 days of their last exposure to the patient (Table 2), including 153 (9.5%) enrolled the day of their last exposure, likely indicating ongoing exposure. Among enrollees, 1,564 (96.4%) agreed to be monitored using the automated symptom monitoring, whereas 58 (3.6%) required direct monitoring. Enrollees using automated symptom monitoring preferred text message (976; 60.2%), followed by texted weblink (342; 21.1%), telephone call (127; 7.8%), and e-mailed weblink (119; 7.3%). Most enrollees (870; 59.0%) preferred an evening contact time. TABLE 2 Enrollment details and monitoring preferences among contacts* of confirmed or probable COVID-19 † patients enrolled in an automated, web-based symptom monitoring tool (Sara Alert) — Maine, May 14–June 26, 2020 Characteristic No. (%) Total 1,622 (100) Interval from last exposure to enrollment (days) 0 153 (9.5) 1 47 (2.9) 2 275 (17.1) 3 153 (9.5) 4 208 (12.9) 5 166 (10.3) 6 163 (10.1) ≥7 447 (27.7) Missing date of last exposure 10 (—) Preferred contact method E-mailed weblink 119 (7.3) Text message 976 (60.2) Texted weblink 342 (21.1) Telephone call 127 (7.8) Direct monitoring§ 58 (3.6) Preferred contact time Morning 479 (32.5) Afternoon 126 (8.5) Evening 870 (59.0) Not recorded 147 (—) No. of persons in household enrolled ¶ 1 673 (70.6) 2 125 (13.1) 3 75 (7.9) 4 33 (3.5) 5 21 (2.2) ≥6 27 (2.7) Abbreviation: COVID-19 = coronavirus disease 2019. * Defined as persons who were within 6 feet of an infectious person (symptomatic persons, 2 days before symptom onset to at least 10 days following symptom onset; asymptomatic persons, 2 days before collection of a specimen that resulted in a positive test to 10 days following specimen collection date) for ≥15 minutes (≥30 minutes before May 29). † Probable cases had either clinical criteria or epidemiologic evidence of exposure (contact with a person with a confirmed or probable COVID-19 case or contact with a person with clinically compatible illness or linkage to a person with confirmed COVID-19), or met vital records criteria (a death certificate listing COVID-19 or SARS-CoV-2 as a cause of death or a significant condition contributing to death with no confirmatory laboratory testing performed for COVID-19). Confirmed cases had confirmatory laboratory evidence of SARS-CoV-2 infection. COVID-19 signs and symptoms included cough, difficulty breathing, fever, chills, shaking with chills (rigors), muscle pain, headache, sore throat, and new loss of taste or smell. § Direct monitoring refers to contacts who did not want to be, or could not be, enrolled for automated monitoring. For these contacts, Maine CDC staff members called contacts daily until the end of their quarantine period. ¶ Based on address reported at time of enrollment. Among all enrollees, 231 (14.2%) reported symptoms or had a positive test result. Among these enrollees, 41 (17.7%) were determined not to have COVID-19, including 24 who received negative test results and 17 whose symptoms did not meet those specified by the case definition; these 41 enrollees were reenrolled in Sara Alert for the remainder of their quarantine. Among all enrollees, 190 (11.7%) met the COVID-19 case definition. Among these 190 persons, 127 (66.8%) were confirmed to have COVID-19, and 63 (33.2%) were considered to have probable cases (Table 3). Among all persons with probable and confirmed cases, median age was 32 years (range = 0–93 years); 99 (52.1%) were female. Race data were available for 186 (97.9%) patients, among whom 98 (52.7%) identified as white and 81 (43.5%) as black/African American. Ethnicity was available for 182 (95.8%) patients, six (3.3%) of whom identified as Hispanic/Latino. Exposure was self-reported for 165 (86.8%) patients; household exposure was most common (112; 67.9%). COVID-19 symptoms were reported for 136 (74.3%) patients. Four (2.1%) patients were hospitalized, and one (0.5%) died. During May 14–July 10, Maine reported 1,869 total COVID-19 cases †† ; thus, approximately 10% of Maine’s COVID-19 patients were identified among Sara Alert enrollees. TABLE 3 Characteristics of contacts* of confirmed or probable COVID-19 † patients enrolled in an automated, web-based symptom monitoring tool (Sara Alert) who developed COVID-19 during quarantine—Maine, May 14–June 26, 2020 Characteristic No. (%)§ Total persons with COVID-19 190 (100) Case status Confirmed 127 (66.8) Probable 63 (33.2) Reported symptoms Yes 136 (74.3) No 47 (25.7) Missing 7 (—) Age, yrs, median (range) 32 (0–93) Sex Female 99 (52.1) Male 91 (47.9) Race Asian/Pacific Islander 3 (1.6) Black/African American 81 (43.5) White 98 (52.7) Other 4 (2.2) Unknown 4 (—) Ethnicity Hispanic or Latino 6 (3.3) Not Hispanic or Latino 176 (96.7) Missing 8 (—) Self-reported exposure settings ¶ Household 112 (67.9) Community 29 (17.6) Health care 26 (15.8) Unknown 25 (—) Hospitalized Yes 4 (2.1) No 186 (97.9) Died from COVID-19 Yes 1 (0.5) No 189 (99.5) Abbreviation: COVID-19 = coronavirus disease 2019. * Defined as persons who were within 6 feet of an infectious person (symptomatic persons, 2 days before symptom onset to at least 10 days following symptom onset; asymptomatic persons, 2 days before collection of a specimen that resulted in a positive test to 10 days following specimen collection date) for ≥15 minutes (≥30 minutes before May 29). † Probable cases had either clinical criteria or epidemiologic evidence of exposure (contact with a person with a confirmed or probable COVID-19 case or contact with a person with clinically compatible illness or linkage to a person with confirmed COVID-19), or met vital records criteria (a death certificate listing COVID-19 or SARS-CoV-2 as a cause of death or a significant condition contributing to death with no confirmatory laboratory testing performed for COVID-19). Confirmed cases had confirmatory laboratory evidence of SARS-CoV-2 infection. COVID-19 signs and symptoms included cough, difficulty breathing, fever, chills, shaking with chills (rigors), muscle pain, headache, sore throat, and new loss of taste or smell. § Percentage calculated among enrollees with nonmissing information. ¶ Two contacts reported multiple exposure types. Discussion Contact tracing and symptom monitoring encourages exposed persons to quarantine while providing health departments an opportunity to promptly and proactively identify symptomatic persons, likely reducing SARS-CoV-2 transmission ( 5 ). Because contact tracing can be resource intensive, using an automated symptom monitoring tool can reduce needed resources ( 9 ). Contact tracing and the resulting postexposure quarantine and monitoring identified 190 (10%) of Maine’s 1,869 reported COVID-19 cases during May 14–July 10. These findings suggest that using a symptom monitoring tool with options to accommodate enrollees’ preferences for monitoring method, time of day, and language, might be important for increasing enrollment and improving contact monitoring. Almost all (96.4%) monitored contacts chose automated over direct symptom monitoring. For most of this study period, Sara Alert provided messages in English only, with Spanish added June 10. Enrollees spoke a variety of languages, and French and Somali options were added after this study concluded. Although the use of automated symptom monitoring tools might reduce staffing and resources needed to conduct active monitoring of contacts, there continues to be a considerable workload associated with contact enrollment, direct monitoring for nonparticipating contacts and follow-up of nonrespondents ( 10 ). Maine CDC dedicates approximately 500 person-hours each week to enrolling and monitoring contacts using Sara Alert. Substantial human resources will likely be required to operate any contact tracing and monitoring program. By identifying options that meet communication and accessibility needs of their specific populations, jurisdictions can maximize available resources. However, continued support for jurisdictions to build and maintain contact tracing capacity is needed. The findings in this report are subject to at least four limitations. First, determining the overall number of contacts identified by all Maine cases was not possible. Contact records in NBS sometimes referenced locations rather than persons, some contacts had no working telephone number or accompanying e-mail address, and an untracked number of contacts refused monitoring, so were not enrolled. Thus, enrollees described in this analysis do not represent the total number of contacts of COVID-19 patients in Maine. Second, during the study period, Sara Alert data extracts did not distinguish between contacts lost to follow-up and those removed based on symptom reporting, making compliance difficult to ascertain. Third, enrollees were not required to be tested for SARS-CoV-2, therefore enrollees with asymptomatic COVID-19 who were not tested were not identified as cases. Finally, although each person was given guidance on quarantine recommendations, adherence was not assessed and is unknown. Using digital tools in support of a comprehensive contact tracing strategy can make the contact tracing and monitoring process faster and more efficient, as well as provide epidemiologic and clinical data which might result in an improved understanding of COVID-19. Although most contacts in communication with Maine CDC opted to enroll in automated symptom monitoring, the contact tracing program, including contact identification, communication, and monitoring, continues to require resources, including staffing. Automated monitoring tools can augment traditional contact tracing; however, they cannot take the place of a large, trained public health workforce required for a comprehensive COVID-19 response. Summary What is already known about this topic? Identification and quarantine of contacts of COVID-19 patients can reduce SARS-CoV-2 transmission. What is added by this report? Maine found that using automated symptom monitoring as a part of the state’s contact tracing program was well received, with the majority of monitored contacts (96.4%) agreeing to automated symptom monitoring. Automated symptom monitoring promptly identified COVID-19 diagnoses among monitored contacts. Among 1,622 persons enrolled into an automated symptom monitoring system, 190 (11.7%) developed COVID-19. What are the implications for public health practice? Prompt case investigation can rapidly identify contacts and recommend quarantine, reducing additional exposures and transmission. Automated tools, available in multiple languages and formats, might improve contact tracing programs and reduce resource needs, including staffing.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

          Background: A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in China in December 2019. There is limited support for many of its key epidemiologic features, including the incubation period for clinical disease (coronavirus disease 2019 [COVID-19]), which has important implications for surveillance and control activities. Objective: To estimate the length of the incubation period of COVID-19 and describe its public health implications. Design: Pooled analysis of confirmed COVID-19 cases reported between 4 January 2020 and 24 February 2020. Setting: News reports and press releases from 50 provinces, regions, and countries outside Wuhan, Hubei province, China. Participants: Persons with confirmed SARS-CoV-2 infection outside Hubei province, China. Measurements: Patient demographic characteristics and dates and times of possible exposure, symptom onset, fever onset, and hospitalization. Results: There were 181 confirmed cases with identifiable exposure and symptom onset windows to estimate the incubation period of COVID-19. The median incubation period was estimated to be 5.1 days (95% CI, 4.5 to 5.8 days), and 97.5% of those who develop symptoms will do so within 11.5 days (CI, 8.2 to 15.6 days) of infection. These estimates imply that, under conservative assumptions, 101 out of every 10 000 cases (99th percentile, 482) will develop symptoms after 14 days of active monitoring or quarantine. Limitation: Publicly reported cases may overrepresent severe cases, the incubation period for which may differ from that of mild cases. Conclusion: This work provides additional evidence for a median incubation period for COVID-19 of approximately 5 days, similar to SARS. Our results support current proposals for the length of quarantine or active monitoring of persons potentially exposed to SARS-CoV-2, although longer monitoring periods might be justified in extreme cases. Primary Funding Source: U.S. Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, and Alexander von Humboldt Foundation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts

            Summary Background Isolation of cases and contact tracing is used to control outbreaks of infectious diseases, and has been used for coronavirus disease 2019 (COVID-19). Whether this strategy will achieve control depends on characteristics of both the pathogen and the response. Here we use a mathematical model to assess if isolation and contact tracing are able to control onwards transmission from imported cases of COVID-19. Methods We developed a stochastic transmission model, parameterised to the COVID-19 outbreak. We used the model to quantify the potential effectiveness of contact tracing and isolation of cases at controlling a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-like pathogen. We considered scenarios that varied in the number of initial cases, the basic reproduction number (R 0), the delay from symptom onset to isolation, the probability that contacts were traced, the proportion of transmission that occurred before symptom onset, and the proportion of subclinical infections. We assumed isolation prevented all further transmission in the model. Outbreaks were deemed controlled if transmission ended within 12 weeks or before 5000 cases in total. We measured the success of controlling outbreaks using isolation and contact tracing, and quantified the weekly maximum number of cases traced to measure feasibility of public health effort. Findings Simulated outbreaks starting with five initial cases, an R 0 of 1·5, and 0% transmission before symptom onset could be controlled even with low contact tracing probability; however, the probability of controlling an outbreak decreased with the number of initial cases, when R 0 was 2·5 or 3·5 and with more transmission before symptom onset. Across different initial numbers of cases, the majority of scenarios with an R 0 of 1·5 were controllable with less than 50% of contacts successfully traced. To control the majority of outbreaks, for R 0 of 2·5 more than 70% of contacts had to be traced, and for an R 0 of 3·5 more than 90% of contacts had to be traced. The delay between symptom onset and isolation had the largest role in determining whether an outbreak was controllable when R 0 was 1·5. For R 0 values of 2·5 or 3·5, if there were 40 initial cases, contact tracing and isolation were only potentially feasible when less than 1% of transmission occurred before symptom onset. Interpretation In most scenarios, highly effective contact tracing and case isolation is enough to control a new outbreak of COVID-19 within 3 months. The probability of control decreases with long delays from symptom onset to isolation, fewer cases ascertained by contact tracing, and increasing transmission before symptoms. This model can be modified to reflect updated transmission characteristics and more specific definitions of outbreak control to assess the potential success of local response efforts. Funding Wellcome Trust, Global Challenges Research Fund, and Health Data Research UK.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020

              Older adults are susceptible to severe coronavirus disease 2019 (COVID-19) outcomes as a consequence of their age and, in some cases, underlying health conditions ( 1 ). A COVID-19 outbreak in a long-term care skilled nursing facility (SNF) in King County, Washington that was first identified on February 28, 2020, highlighted the potential for rapid spread among residents of these types of facilities ( 2 ). On March 1, a health care provider at a second long-term care skilled nursing facility (facility A) in King County, Washington, had a positive test result for SARS-CoV-2, the novel coronavirus that causes COVID-19, after working while symptomatic on February 26 and 28. By March 6, seven residents of this second facility were symptomatic and had positive test results for SARS-CoV-2. On March 13, CDC performed symptom assessments and SARS-CoV-2 testing for 76 (93%) of the 82 facility A residents to evaluate the utility of symptom screening for identification of COVID-19 in SNF residents. Residents were categorized as asymptomatic or symptomatic at the time of testing, based on the absence or presence of fever, cough, shortness of breath, or other symptoms on the day of testing or during the preceding 14 days. Among 23 (30%) residents with positive test results, 10 (43%) had symptoms on the date of testing, and 13 (57%) were asymptomatic. Seven days after testing, 10 of these 13 previously asymptomatic residents had developed symptoms and were recategorized as presymptomatic at the time of testing. The reverse transcription–polymerase chain reaction (RT-PCR) testing cycle threshold (Ct) values indicated large quantities of viral RNA in asymptomatic, presymptomatic, and symptomatic residents, suggesting the potential for transmission regardless of symptoms. Symptom-based screening in SNFs could fail to identify approximately half of residents with COVID-19. Long-term care facilities should take proactive steps to prevent introduction of SARS-CoV-2 ( 3 ). Once a confirmed case is identified in an SNF, all residents should be placed on isolation precautions if possible ( 3 ), with considerations for extended use or reuse of personal protective equipment (PPE) as needed ( 4 ). Immediately upon identification of the index case in facility A on March 1, nursing and administrative leadership instituted visitor restrictions, twice-daily assessments of COVID-19 signs and symptoms among residents, and fever screening of all health care personnel at the start of each shift. On March 6, Public Health – Seattle and King County, in collaboration with CDC, recommended infection prevention and control measures, including isolation of all symptomatic residents and use of gowns, gloves, eye protection, facemasks, and hand hygiene for health care personnel entering symptomatic residents’ rooms. A data collection tool was developed to ascertain symptom status and underlying medical conditions for all residents. On March 13, the symptom assessment tool was completed by facility A’s nursing staff members by reviewing screening records of residents for the preceding 14 days and by clinician interview of residents at the time of specimen collection. For residents with significant cognitive impairment, symptoms were obtained solely from screening records. A follow-up symptom assessment was completed 7 days later by nursing staff members. Nasopharyngeal swabs were obtained from all 76 residents who agreed to testing and were present in the facility at the time; oropharyngeal swabs were also collected from most residents, depending upon their cooperation. The Washington State Public Health Laboratory performed one-step real-time RT-PCR assay on all specimens using the SARS-CoV-2 CDC assay protocol, which determines the presence of the virus through identification of two genetic markers, the N1 and N2 nucleocapsid protein gene regions ( 5 ). The Ct, the cycle number during RT-PCR testing when detection of viral amplicons occurs, is inversely correlated with the amount of RNA present; a Ct value <40 cycles denotes a positive result for SARS-CoV-2, with a lower value indicating a larger amount of viral RNA. Residents were assessed for stable chronic symptoms (e.g., chronic, unchanged cough) as well as typical and atypical signs and symptoms of COVID-19. Typical COVID-19 signs and symptoms include fever, cough, and shortness of breath ( 3 ); potential atypical symptoms assessed included sore throat, chills, increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, malaise, headache, nausea, and diarrhea. Residents were categorized as asymptomatic (no symptoms or only stable chronic symptoms) or symptomatic (at least one new or worsened typical or atypical symptom of COVID-19) on the day of testing or during the preceding 14 days. Residents with positive test results and were asymptomatic at time of testing were reevaluated 1 week later to ascertain whether any symptoms had developed in the interim. Those who developed new symptoms were recategorized as presymptomatic. Ct values were compared for the recategorized symptom groups using one-way analysis of variance (ANOVA) for all residents with positive test results for SARS-CoV-2. Analyses were conducted using SAS statistical software (version 9.4; SAS Institute). On March 13, among the 82 residents in facility A; 76 (92.7%) underwent symptom assessment and testing; three (3.7%) refused testing, two (2.4%) who had COVID-19 symptoms were transferred to a hospital before testing, and one (1.2%) was unavailable. Among the 76 tested residents, 23 (30.3%) had positive test results. Demographic characteristics were similar among the 53 (69.7%) residents with negative test results and the 23 (30.3%) with positive test results (Table 1). Among the 23 residents with positive test results, 10 (43.5%) were symptomatic, and 13 (56.5%) were asymptomatic. Eight symptomatic residents had typical COVID-19 symptoms, and two had only atypical symptoms; the most common atypical symptoms reported were malaise (four residents) and nausea (three). Thirteen (24.5%) residents who had negative test results also reported typical and atypical COVID-19 symptoms during the 14 days preceding testing. TABLE 1 Demographics and reported symptoms for residents of a long-term care skilled nursing facility at time of testing* (N = 76), by SARS-CoV-2 test results — facility A, King County, Washington, March 2020 Characteristic Initial SARS-CoV-2 test results Negative, no. (%) Positive, no. (%) Overall 53 (100) 23 (100) Women 32 (60.4) 16 (69.6) Age, mean (SD) 75.1 (10.9) 80.7 (8.4) Current smoker† 7 (13.2) 1 (4.4) Long-term admission type to facility A 35 (66.0) 15 (65.2) Length of stay in facility A before test date, days, median (IQR) 94 (40–455) 70 (21–504) Symptoms in last 14 days Symptomatic 13 (24.5) 10 (43.5) At least one typical COVID-19 symptom§ 9 (17.0) 8 (34.8) Only atypical COVID-19 symptoms¶ 4 (7.5) 2 (8.7) Asymptomatic 40 (75.5) 13 (56.5) No symptoms 32 (60.4) 8 (34.8) Only stable, chronic symptoms 8 (15.1) 5 (21.7) Specific signs and symptoms reported as new or worse in last 14 days Typical symptoms Fever 3 (5.7) 1 (4.3) Cough 6 (11.3) 7 (30.4) Shortness of breath 0 (0) 1 (4.4) Atypical symptoms Malaise 1 (1.9) 4 (17.4) Nausea 0 (0) 3 (13.0) Sore throat 2 (3.8) 2 (8.7) Confusion 2 (3.8) 1 (4.4) Dizziness 1 (1.9) 1 (4.4) Diarrhea 3 (5.7) 1 (4.4) Rhinorrhea/Congestion 1 (1.9) 0 (0) Myalgia 0 (0) 0 (0) Headache 0 (0) 0 (0) Chills 0 (0) 0 (0) Any preexisting medical condition listed 53 (100) 22 (95.7) Specific conditions** Chronic lung disease 16 (30.2) 10 (43.5) Diabetes 20 (37.7) 9 (39.1) Cardiovascular disease 36 (67.9) 20 (87.0) Cerebrovascular accident 19 (35.9) 8 (34.8) Renal disease 18 (34.0) 9 (39.1) Received hemodialysis 2 (3.8) 2 (8.7) Cognitive Impairment 28 (52.8) 13 (56.5) Obesity 11 (20.8) 6 (26.1) Abbreviations: COVID-19 = coronavirus disease 2019; IQR = interquartile range, SD = standard deviation. * Testing performed on March 13, 2020. † Unknown for one resident with negative test results. § Typical symptoms include fever, cough, and shortness of breath. ¶ Atypical symptoms include chills, malaise, sore throat, increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, headache, nausea, and diarrhea. ** Residents might have multiple conditions. One week after testing, the 13 residents who had positive test results and were asymptomatic on the date of testing were reassessed; 10 had developed symptoms and were recategorized as presymptomatic at the time of testing (Table 2). The most common signs and symptoms that developed were fever (eight residents), malaise (six), and cough (five). The mean interval from testing to symptom onset in the presymptomatic residents was 3 days. Three residents with positive test results remained asymptomatic. TABLE 2 Follow-up symptom assessment 1 week after testing for SARS-CoV-2 among 13 residents of a long-term care skilled nursing facility who were asymptomatic on March 13, 2020 (date of testing) and had positive test results — facility A, King County, Washington, March 2020 Symptom status 1 week after testing No. (%) Asymptomatic 3 (23.1) Developed new symptoms 10 (76.7) Fever 8 (61.5) Malaise 6 (46.1) Cough 5 (38.4) Confusion 4 (30.8) Rhinorrhea/Congestion 4 (30.8) Shortness of breath 3 (23.1) Diarrhea 3 (23.1) Sore throat 1 (7.7) Nausea 1 (7.7) Dizziness 1 (7.7) Real-time RT-PCR Ct values for both genetic markers among residents with positive test results for SARS-CoV-2 ranged from 18.6 to 29.2 (symptomatic [typical symptoms]), 24.3 to 26.3 (symptomatic [atypical symptoms only]), 15.3 to 37.9 (presymptomatic), and 21.9 to 31.0 (asymptomatic) (Figure). There were no significant differences between the mean Ct values in the four symptom status groups (p = 0.3). FIGURE Cycle threshold (Ct) values* for residents of a long-term care skilled nursing facility with positive test results for SARS-CoV-2 by real-time reverse transcription–polymerase chain reaction on March 13, 2020 (n = 23), by symptom status†,§ at time of test — facility A, King County, Washington * Ct values are the number of cycles needed for detection of each genetic marker identified by real-time reverse transcription–polymerase chain reaction testing. A lower Ct value indicates a higher amount of viral RNA. Paired values for each resident are depicted using a different shape. Each resident has two Ct values for the two genetic markers (N1 and N2 nucleocapsid protein gene regions). † Typical symptoms include fever, cough, and shortness of breath. § Atypical symptoms include chills, malaise, sore throat, increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, headache, nausea, and diarrhea. The figure is a scatter plot showing the cycle threshold values for residents of a long-term care skilled nursing facility with positive test results for SARS-CoV-2 by real-time reverse transcription–polymerase chain reaction on March 13, 2020 (n = 23), by symptom status at time of test, in facility A, King County, Washington. Discussion Sixteen days after introduction of SARS-CoV-2 into facility A, facility-wide testing identified a 30.3% prevalence of infection among residents, indicating very rapid spread, despite early adoption of infection prevention and control measures. Approximately half of all residents with positive test results did not have any symptoms at the time of testing, suggesting that transmission from asymptomatic and presymptomatic residents, who were not recognized as having SARS-CoV-2 infection and therefore not isolated, might have contributed to further spread. Similarly, studies have shown that influenza in the elderly, including those living in SNFs, often manifests as few or atypical symptoms, delaying diagnosis and contributing to transmission ( 6 – 8 ). These findings have important implications for infection control. Current interventions for preventing SARS-CoV-2 transmission primarily rely on presence of signs and symptoms to identify and isolate residents or patients who might have COVID-19. If asymptomatic or presymptomatic residents play an important role in transmission in this population at high risk, additional prevention measures merit consideration, including using testing to guide cohorting strategies or using transmission-based precautions for all residents of a facility after introduction of SARS-CoV-2. Limitations in availability of tests might necessitate taking the latter approach at this time. Although these findings do not quantify the relative contributions of asymptomatic or presymptomatic residents to SARS-CoV-2 transmission in facility A, they suggest that these residents have the potential for substantial viral shedding. Low Ct values, which indicate large quantities of viral RNA, were identified for most of these residents, and there was no statistically significant difference in distribution of Ct values among the symptom status groups. Similar Ct values were reported in asymptomatic adults in China who were known to transmit SARS-CoV-2 ( 9 ). Studies to determine the presence of viable virus from these specimens are currently under way. SNFs have additional infection prevention and control challenges compared with those of assisted living or independent living long-term care facilities. For example, SNF residents might be in shared rooms rather than individual apartments, and there is often prolonged and close contact between residents and health care providers related to the residents’ medical conditions and cognitive function. The index patient in this outbreak was a health care provider, which might have contributed to rapid spread in the facility. In addition, health care personnel in all types of long-term care facilities might have limited experience with proper use of PPE. Symptom ascertainment and room isolation can be exceptionally challenging in elderly residents with neurologic conditions, including dementia. In addition, symptoms of COVID-19 are common and might have multiple etiologies in this population; 24.5% of facility A residents with negative test results for SARS-CoV-2 reported typical or atypical symptoms. The findings in this report are subject to at least two limitations. First, accurate symptom ascertainment in persons with cognitive impairment and other disabilities is challenging; however, this limitation is estimated to be representative of symptom data collected in most SNFs, and thus, these findings might be generalizable. Second, because this analysis was conducted among residents of an SNF, it is not known whether findings apply to the general population, including younger persons, those without underlying medical conditions, or similarly aged populations in the general community. This analysis suggests that symptom screening could initially fail to identify approximately one half of SNF residents with SARS-CoV-2 infection. Unrecognized asymptomatic and presymptomatic infections might contribute to transmission in these settings. During the current COVID-19 pandemic, SNFs and all long-term care facilities should take proactive steps to prevent introduction of SARS-CoV-2, including restricting visitors except in compassionate care situations, restricting nonessential personnel from entering the building, asking staff members to monitor themselves for fever and other symptoms, screening all staff members at the beginning of their shift for fever and other symptoms, and supporting staff member sick leave, including for those with mild symptoms ( 3 ). Once a facility has a case of COVID-19, broad strategies should be implemented to prevent transmission, including restriction of resident-to-resident interactions, universal use of facemasks for all health care personnel while in the facility, and if possible, use of CDC-recommended PPE for the care of all residents (i.e., gown, gloves, eye protection, N95 respirator, or, if not available, a face mask) ( 3 ). In settings where PPE supplies are limited, strategies for extended PPE use and limited reuse should be employed ( 4 ). As testing availability improves, consideration might be given to test-based strategies for identifying residents with SARS-CoV-2 infection for the purpose of cohorting, either in designated units within a facility or in a separate facility designated for residents with COVID-19. During the COVID-19 pandemic, collaborative efforts are crucial to protecting the most vulnerable populations. Summary What is already known about this topic? Once SARS-CoV-2 is introduced in a long-term care skilled nursing facility (SNF), rapid transmission can occur. What is added by this report? Following identification of a case of coronavirus disease 2019 (COVID-19) in a health care worker, 76 of 82 residents of an SNF were tested for SARS-CoV-2; 23 (30.3%) had positive test results, approximately half of whom were asymptomatic or presymptomatic on the day of testing. What are the implications for public health practice? Symptom-based screening of SNF residents might fail to identify all SARS-CoV-2 infections. Asymptomatic and presymptomatic SNF residents might contribute to SARS-CoV-2 transmission. Once a facility has confirmed a COVID-19 case, all residents should be cared for using CDC-recommended personal protective equipment (PPE), with considerations for extended use or reuse of PPE as needed.
                Bookmark

                Author and article information

                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb. Mortal. Wkly. Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                07 August 2020
                07 August 2020
                : 69
                : 31
                : 1026-1030
                Affiliations
                Maine Center for Disease Control and Prevention, Augusta, Maine; CDC COVID-19 Response Team; University of Southern Maine, Portland, Maine.
                Author notes
                Corresponding author: Anna Krueger, Anna.Krueger@ 123456Maine.gov .
                Article
                mm6931e2
                10.15585/mmwr.mm6931e2
                7454893
                32759918
                ef1c81e0-10a8-4d41-be9b-472b27864c71

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content44

                Cited by13

                Most referenced authors312